Favorable response of metastatic merkel cell carcinoma to targeted 177Lu-DOTATATE therapy: Will PRRT evolve to become an important approach in receptor-positive cases?

Basu, SandipRanade, R.2017-03-202017-03-202016Journal of Nuclear Medicine Technology, 2016. Vol. 44 (2): pp. 85-87http://hdl.handle.net/123456789/142424644 bytestext/htmlenMerkel cell carcinoma177Lu-DOTATATEpeptide receptor radionuclide therapyPRRTFavorable response of metastatic merkel cell carcinoma to targeted 177Lu-DOTATATE therapy: Will PRRT evolve to become an important approach in receptor-positive cases?Article